Amneal Pharmaceuticals Dividend
Dividend criteria checks 0/6
Amneal Pharmaceuticals, Inc. does not have a record of paying a dividend.
|Industry average yield||2.6%|
|Next dividend pay date||n/a|
|Ex dividend date||n/a|
|Dividend per share||US$0|
|Earnings per share||-US$0.87|
|Dividend yield forecast in 3Y||0%|
Recent dividend updates
Amneal Pharmaceuticals: Risk Still PersistsJan 23
Amneal Pharma reaffirms 2022 guidanceJan 10
Amneal joins hands with Orion to commercialize generic products in Europe and more countriesJan 04
Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt LoadDec 20
Amneal Pharmaceuticals large shareholder TPG cuts stakeDec 14
FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203Nov 11
Amneal Pharmaceuticals Q3 2022 Earnings PreviewNov 03
Amneal Pharmaceuticals: A Small 'Thumbs Up'Oct 28
Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance SheetSep 01
Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatmentAug 31
Amneal Pharmaceuticals Q2 2022 Earnings PreviewAug 04
Amneal Pharmaceuticals (NYSE:AMRX) Takes On Some Risk With Its Use Of DebtApr 16
Amneal Pharmaceuticals: Generics And Biosimilars Play Has Strong Upside Potential Under New / Old ManagementMar 30
Revisiting Amneal Pharmaceuticals After Its CEO Buys SharesDec 22
Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance SheetNov 23
FDA accepts Amneal's Bevacizumab BLA for review, shares riseJun 17
Amneal Pharmaceuticals Q1 2021 Earnings PreviewMay 06
Is Amneal Pharmaceuticals (NYSE:AMRX) A Risky Investment?Apr 28
What Percentage Of Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Shares Do Insiders Own?Feb 28
A Closer Look At Amneal Pharmaceuticals, Inc.'s (NYSE:AMRX) Uninspiring ROEFeb 05
Amneal to buy Kashiv Bio for upfront price of $100MJan 12
These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt ExtensivelyJan 10
Are Amneal Pharmaceuticals's (NYSE:AMRX) Statutory Earnings A Good Reflection Of Its Earnings Potential?Dec 06
Amneal Pharmaceuticals Q3 2020 Earnings PreviewNov 05
Dividend Yield vs Market
|Amneal Pharmaceuticals Dividend Yield vs Market|
|Market Bottom 25% (US)||1.5%|
|Market Top 25% (US)||4.2%|
|Industry Average (Pharmaceuticals)||2.6%|
|Analyst forecast in 3 Years (AMRX)||0%|
Notable Dividend: Unable to evaluate AMRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AMRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
|Month||Dividend Per Share (annual)||Avg. Yield (%)|
Stable Dividend: Insufficient data to determine if AMRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMRX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: AMRX is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AMRX has not reported any payouts.